KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other Non-Current Liabilities: 2009-2025

Historic Other Non-Current Liabilities for Rigel Pharmaceuticals (RIGL) over the last 12 years, with Mar 2025 value amounting to $40.0 million.

  • Rigel Pharmaceuticals' Other Non-Current Liabilities changed negligibly% to $40.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $40.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $40.0 million for FY2024, which is 0.09% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Other Non-Current Liabilities stood at $40.0 million for Q1 2025, which was down 0.00% from $40.0 million recorded in Q4 2024.
  • Rigel Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $57.5 million for Q1 2021, and its period low was $38.8 million during Q3 2023.
  • In the last 3 years, Rigel Pharmaceuticals' Other Non-Current Liabilities had a median value of $40.0 million in 2025 and averaged $40.2 million.
  • In the last 5 years, Rigel Pharmaceuticals' Other Non-Current Liabilities skyrocketed by 1,050.66% in 2021 and then dropped by 20.94% in 2023.
  • Rigel Pharmaceuticals' Other Non-Current Liabilities (Quarterly) stood at $52.7 million in 2021, then declined by 19.84% to $42.3 million in 2022, then decreased by 5.49% to $39.9 million in 2023, then rose by 0.09% to $40.0 million in 2024, then dropped by 0.00% to $40.0 million in 2025.
  • Its Other Non-Current Liabilities was $40.0 million in Q1 2025, compared to $40.0 million in Q4 2024 and $40.0 million in Q3 2024.